XML 33 R21.htm IDEA: XBRL DOCUMENT
v3.26.1

Stockholders’ (Deficit) Equity | 3 Months Ended
--- | ---
Mar. 31, 2026
Stockholders’ (Deficit) Equity [Abstract] |
STOCKHOLDERS’ (DEFICIT) EQUITY | NOTE 15 – STOCKHOLDERS’ (DEFICIT) EQUITY Shares Cancelled During the three months ended March 31, 2026, the Company cancelled 34,886 shares of Common Stock to satisfy tax withholding obligations related to equity awards. Warrants A summary of the Common Stock underlying the warrants activity (including both liability and equity classified instruments) is presented below (in thousands, except number of shares, exercise price, and years data):
|  | Three Months Ended March 31, 2026 |
|  | Number of Shares of Common Stock Underlying Warrants |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Life in Years |  |  | Intrinsic Value |
Outstanding, December 31, 2025 |  |  | 7,020,932 |  |  | $ | 22.47 |  |  |  | - |  |  | $ | 7,607 |
Issued |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Exercised |  |  | - |  |  |  | - |  |  |  | - |  |  |  | - |
Expired |  |  | (270 | ) |  |  | 43,499.00 |  |  |  | - |  |  |  | - |
Outstanding, March 31, 2026 |  |  | 7,020,662 |  |  | $ | 22.47 |  |  |  | - |  |  | $ | 7,607 |
Exercisable, March 31, 2026 |  |  | 7,020,662 |  |  | $ | 22.47 |  |  |  | - |  |  |  | - |
A summary of outstanding and exercisable Common Stock underlying the warrants is presented below:
March 31, 2026 |
Common Stock Underlying Warrants Outstanding |  |  | Common Stock Underlying Warrants Exercisable |
Exercise Price |  |  | Number of Shares |  |  | Weighted Average Remaining Life in Years |  |  | Number of Shares |
$ | 34.45 |  |  |  | 907,115 |  |  |  | N/A |  |  |  | 907,115 |
$ | 32.30 |  |  |  | 405 |  |  |  | N/A |  |  |  | 405 |
$ | 27.75 |  |  |  | 4,557,223 |  |  |  | N/A |  |  |  | 4,557,223 |
$ | 26.50 |  |  |  | 270 |  |  |  | 0.4 |  |  |  | 270 |
$ | 22.80 |  |  |  | 75 |  |  |  | 4.25 |  |  |  | 75 |
$ | 0.01 |  |  |  | 1,555,574 |  |  |  | N/A |  |  |  | 1,555,574 |
|  |  |  |  | 7,020,662 |  |  |  | 0.0 |  |  |  | 7,020,662 |
During the three months ended March 31, 2026, the Company sold 1,335,766 shares of Common Stock under the Second Amended and Restated Sales Agreement (the “Second Amended and Restated Sales Agreement”) for net proceeds after fees of approximately $5.5 million at an average price of $3.87 per share. The Company also cancelled 34,886 shares of Common Stock related to tax withholdings on Common Stock awards. Stock Repurchase Program During the three months ended March 31, 2026, no shares of Common Stock were repurchased by the Company under its previously announced stock repurchase program (the “Stock Repurchase Program”).

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration